Telix Pharmaceuticals Ltd Revenue Growth Rates (TLX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Telix Pharmaceuticals Ltd  (NASDAQ: TLX)
 

TLX's Revenue Growth by Quarter and Year

Telix Pharmaceuticals Ltd's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TLX Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 803.44
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 803.44





TLX Revenue fourth quarter 2024 Y/Y Growth Comment
Telix Pharmaceuticals Ltd showed record Revenue improvement in the fourth quarter 2024 with 2.65% from the fourth quarter 2024 2023, to $ 803.44 millions.
This represents worst decline in recent Company history.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Telix Pharmaceuticals Ltd' s Revenue increase of 2.65% ranks overall at the positon no. 2117 in the fourth quarter 2024.


TLX Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December 2.65 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   2.65 % - - -

Financial Statements
Telix Pharmaceuticals Ltd's fourth quarter 2024 Revenue $ 803.44 millions TLX's Income Statement
Telix Pharmaceuticals Ltd's fourth quarter 2023 Revenue $ 782.68 millions Quarterly TLX's Income Statement


TLX Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   2.65 % - - -


Back to TLX Growth rate Comparisons >> Back to TLX Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #333
Overall #2117

Revenue Y/Y Growth Statistics
High Average Low
2.65 % 2.65 % 2.65 %
 
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #333
Overall #2117
Revenue Y/Y Growth Statistics
High Average Low
2.65 % 2.65 % 2.65 %
 

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Telix Pharmaceuticals Ltd's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TLX's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TLX's IV. Quarter Q/Q Revenue Comment


Telix Pharmaceuticals Ltd's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 803.79 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 55.61 % - - - -
Year on Year Revenue Growth Overall Ranking # 2094 # 0 # # #
Seqeuential Revenue Change (TTM) 55.61 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
Telix Pharmaceuticals Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 55.61% year on year, to $ 804 millions if the fiscal year would have ended in Dec 31 2025.
Telix Pharmaceuticals Ltd's trailing twelve months Revenue growth was higher than company's average 2.65% and higher than % growth in .

In the Healthcare sector 334 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2094.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 131
Healthcare Sector # 335
Overall # 2094

Revenue TTM Y/Y Growth Statistics
High Average Low
2.65 %
 2.65 %
2.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 47
Sector # 92
S&P 500 # 326
Cumulative Revenue growth Comment
Telix Pharmaceuticals Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 55.61% year on year, to $ 804 millions if the fiscal year would have ended in Dec 31 2025.
Telix Pharmaceuticals Ltd's trailing twelve months Revenue growth was higher than company's average 2.65% and higher than % growth in .
The momentum is even more impressive from twelve months ended exhibited at 55.61 % increase from $516.55 millions in the period from to .

In the Healthcare sector 334 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 2094.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 131
Healthcare Sector # 335
Overall # 2094

Revenue TTM Y/Y Growth Statistics
High Average Low
2.65 %
2.65 %
2.65 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 47
Sector # 92
S&P 500 # 326




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TLX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Carlsmed Inc 4.63%$ 4.630 millions
Abbott Laboratories4.42%$ 4.420 millions
Grifols Sa4.32%$ 4.321 millions
Biontech Se4.32%$ 4.318 millions
Ufp Technologies Inc 4.08%$ 4.076 millions
Retractable Technologies Inc4.03%$ 4.029 millions
Lantheus Holdings Inc 3.92%$ 3.915 millions
P3 Health Partners Inc 3.81%$ 3.811 millions
Bio rad Laboratories Inc 3.78%$ 3.780 millions
Personalis Inc 3.24%$ 3.244 millions
Seer Inc 3.14%$ 3.144 millions
Agilon Health Inc 3.09%$ 3.087 millions
Zoetis Inc 3.02%$ 3.021 millions
Valneva Se3.00%$ 2.996 millions
Telix Pharmaceuticals Ltd2.65%$ 2.652 millions
Enovis Corp2.64%$ 2.635 millions
Regeneron Pharmaceuticals Inc 2.51%$ 2.510 millions
Fonar Corporation2.39%$ 2.393 millions
Msa Safety Inc2.39%$ 2.391 millions
Surgery Partners Inc 2.38%$ 2.383 millions
Quidelortho Corp2.23%$ 2.232 millions
Heron Therapeutics Inc 2.20%$ 2.204 millions
Bioventus Inc 2.10%$ 2.098 millions
Inogen Inc 2.05%$ 2.048 millions
3m Company2.05%$ 2.047 millions
Tandem Diabetes Care Inc 1.84%$ 1.843 millions
Vsee Health Inc 1.72%$ 1.724 millions
Becton Dickinson And Company1.63%$ 1.625 millions
Orthofix Medical Inc 1.61%$ 1.615 millions
Geron Corporation1.53%$ 1.529 millions


About Telix Pharmaceuticals Ltd Revenue Growth Rates (TLX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Telix Pharmaceuticals Ltd (CIK 2007191).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-009943
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Telix Pharmaceuticals Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.